Phase III under way

New York - Adjuvant therapy with a macrophage-activating growth factor appears to prolong survival in high-risk melanoma, Lynn E. Spitler, M.D., said.

Related Videos

Related Content

The Mainstream Patient: February 7

February 7th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

The Art of Smelling Good

February 7th 2023

The Cutaneous Connection: An Inside Look of the Inclusive Atlas

November 4th 2021

The Weekly Roundup: January 30-February 3

February 3rd 2023

Losing a Malpractice Case May Depend on Where You Live

February 3rd 2023

The Mainstream Patient: February 7

February 7th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

The Art of Smelling Good

February 7th 2023

The Cutaneous Connection: An Inside Look of the Inclusive Atlas

November 4th 2021

The Weekly Roundup: January 30-February 3

February 3rd 2023

Losing a Malpractice Case May Depend on Where You Live

February 3rd 2023

The Mainstream Patient: February 7

February 7th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

The Art of Smelling Good

February 7th 2023

The Cutaneous Connection: An Inside Look of the Inclusive Atlas

November 4th 2021

The Weekly Roundup: January 30-February 3

February 3rd 2023

Losing a Malpractice Case May Depend on Where You Live

February 3rd 2023

Related Content

The Mainstream Patient: February 7

Article

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

Podcast

The Art of Smelling Good

Article

The Cutaneous Connection: An Inside Look of the Inclusive Atlas

Podcast

The Weekly Roundup: January 30-February 3

Article

Losing a Malpractice Case May Depend on Where You Live

Article